Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

AIDS. 2016 Jul 31;30(12):1999-2001. doi: 10.1097/QAD.0000000000001123.

Authors

Stein Schalkwijk¹, Cornelia Feiterna-Sperling, Katharina Weizsäcker, Angela Colbers, Christoph Bührer, Rick Greupink, Frans G M Russel, David Burger; PANNA network

Affiliation

¹ aDepartment of Pharmacy bDepartment of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands cDepartment of Pediatric Pneumology and Immunology dDepartment of Obstetrics eDepartment of Neonatology, Charité Universitätsmedizin, Berlin, Germany.

PMID: 27428578
DOI: 10.1097/QAD.0000000000001123

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Female
HIV Infections / drug therapy*
HIV Integrase Inhibitors / administration & dosage*
HIV-1*
Heterocyclic Compounds, 3-Ring / administration & dosage*
Humans
Oxazines
Piperazines
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Pyridones

Substances

HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir